Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Vigil's rare brain disease drug flunks phase 2 study
The trial missed its biomarker and efficacy endpoints, prompting the Sanofi-bound biotech to stop a long-term extension trial of the TREM2 agonist.
Nick Paul Taylor
Jun 4, 2025 9:45am
J&J shares survival data on KLK2 bispecific in prostate cancer
Jun 2, 2025 6:40am
Merck takes middle dose of ROR ADC forward into phase 3
May 30, 2025 9:51am
Roche links BTK drug to low relapse rate across 96-week MS trial
May 30, 2025 5:19am
Merck KGaA posts tumor data ahead of showdown with Daiichi, Ono
May 28, 2025 8:45am
Gilgamesh links psychedelic to 94% remission rate in depression
May 27, 2025 11:00am
